



Product Quality Research Institute

September 29, 2006

2107 Wilson Blvd.  
Suite 700  
Arlington, VA  
22201-3042

PH: (703) 248-4719  
FX: (703) 525-7136  
www.pqri.org

**PQRI Board of Directors**

Robert A. Lipper, Ph.D., Chair  
Alexander R. Giaquinto, Ph.D.  
Gordon E. Hansen  
Mary Oates, Ph.D.  
Avraham M. Yacobi, Ph.D.

**Steering Committee**

American Association of  
Pharmaceutical Scientists (AAPS)

Biotechnology Industry  
Organization (BIO)

Consumer Healthcare  
Products Association (CHPA)

Generic Pharmaceutical  
Association (GPhA)

International Pharmaceutical  
Aerosol Consortium on  
Research and Science (IPAC-RS)

International Pharmaceutical  
Excipients Council of the  
Americas (IPEC-Americas)

Parenteral Drug Association (PDA)

Pharmaceutical Research and  
Manufacturers of America (PhRMA)

United States Pharmacopeia (USP)

Ms. Helen Winkle, Director  
Office of Pharmaceutical Sciences  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Dear Ms. Winkle:

The Product Quality Research Institute (PQRI) is pleased to submit for FDA's consideration the "*Safety Thresholds and Best Practices for Leachables and Extractables in Orally Inhaled and Nasal Drug Products*" recommendation, which represents the culmination of the PQRI Leachables and Extractables Working Group's efforts over nearly a four year period. Group representation included industry, academia and the various components of the Agency and drew on the vast expertise of the working group members, as well as comprehensive literature and database analysis and evaluation, and extensive laboratory work.

During the period of study and discussion, the L/E Working Group developed a work plan outlining the goals and activities proposed, established two sub groups – the toxicologists and the chemists – gathered data, built consensus, submitted findings for an independent peer review and their work has now received the full endorsement of PQRI's Drug Product Technical Committee and Steering Committee. The complete report is attached for your review.

We look forward to FDA's response to this submission and welcome any questions or clarifications which may assist you in your review. Please do not hesitate to contact me (203-798-5701) if I may assist you further in this regard.

Respectfully submitted,

Gordon Hansen  
Chair, PQRI Steering Committee

cc: Dan Norwood, Chair, Leachables/Extractables Working Group  
Terry Tougas, Chair, Drug Product Technical Committee